Novartis to Acquire Myricx Bio for Up to $1.5B, Adding Cancer-Fighting ADC Payload Platform
ADC payload platformPositive
AI Analysis
Summary
Novartis to acquire Myricx Bio for up to $1.5B to add N-myristoyltransferase inhibitor (NMTi) payload platform for ADC development in cancer treatment. The acquisition targets cancer immunotherapy with differentiated payload technology designed to address limitations of existing ADC approaches.
Outcome Details
Up to $1.5B acquisition
Importance:8/10
Sentiment:
0.70
M&AoncologyADCantibody-drug conjugateNMTi payload
Related Companies
Read the original article
Published by GEN - Genetic Engineering & Biotech News on July 8, 2026 1:20 AM